Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00150332
First received: September 6, 2005
Last updated: May 9, 2011
Last verified: May 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
| Condition | Intervention | Phase |
|---|---|---|
|
Infections, Nosocomial |
Drug: linezolid |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- infection due to methicillin-resistant Staphylococcus aureus
Exclusion Criteria:
- hypersensitivity to linezolid
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00150332
Locations
| Japan | |
| Pfizer Investigational Site | |
| Kamogawa, Chiba, Japan, 296-0041 | |
| Pfizer Investigational Site | |
| Onga-gun, Fukuoka, Japan, 807-0051 | |
| Pfizer Investigational Site | |
| Sappopro, Hokkaido, Japan, 060-8648 | |
| Pfizer Investigational Site | |
| Sapporo, Hokkaido, Japan, 006-8555 | |
| Pfizer Investigational Site | |
| Moriya, Ibaraki, Japan, 302-0118 | |
| Pfizer Investigational Site | |
| Yokohama, Kanagawa, Japan, 236-0051 | |
| Pfizer Investigational Site | |
| Isahaya, Nagasaki, Japan, 854-8501 | |
| Pfizer Investigational Site | |
| Kurashiki, Okayama, Japan, 701-0912 | |
| Pfizer Investigational Site | |
| Kurashiki, Okayama, Japan | |
| Pfizer Investigational Site | |
| Suita, Osaka, Japan, 565-8565 | |
| Pfizer Investigational Site | |
| Iruma-gun, Saitama, Japan, 350-0495 | |
| Pfizer Investigational Site | |
| Kodaira, Tokyo, Japan, 187-0004 | |
| Pfizer Investigational Site | |
| Fukuoka, Japan, 813-0025 | |
| Pfizer Investigational Site | |
| Fukuoka, Japan, 811-0213 | |
| Pfizer Investigational Site | |
| Hiroshima, Japan, 730-8619 | |
| Pfizer Investigational Site | |
| Hiroshima, Japan, 734-8530 | |
| Pfizer Investigational Site | |
| Kyoto, Japan, 615-8256 | |
| Pfizer Investigational Site | |
| Nagasaki, Japan, 852-8501 | |
| Pfizer Investigational Site | |
| Okayama, Japan, 700-8505 | |
| Pfizer Investigational Site | |
| Okayama, Japan, 703-8275 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
No publications provided
| Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer |
| ClinicalTrials.gov Identifier: | NCT00150332 History of Changes |
| Other Study ID Numbers: | M12600067, A5951054 |
| Study First Received: | September 6, 2005 |
| Last Updated: | May 9, 2011 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Additional relevant MeSH terms:
|
Cross Infection Staphylococcal Infections Infection Gram-Positive Bacterial Infections Bacterial Infections Linezolid |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 17, 2013